# A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT04968574** · PHASE2 · COMPLETED · sponsor: **Endeavor Biomedicines, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** taladegib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04968574
- **Lead sponsor:** Endeavor Biomedicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-26
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968574, "A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04968574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*